search
Back to results

A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis

Primary Purpose

Pediculosis Capitis (Head Lice)

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Spinosad Creme Rinse
Sponsored by
ParaPRO LLC
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pediculosis Capitis (Head Lice) focused on measuring Pediculosis capitis, Head Lice, Crawlers, Ova

Eligibility Criteria

2 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Subject must have head lice infestation of at least a mild severity present at baseline of at least 3 live lice and the presence of nits; Subject can be either male or female, 2 years or older Subject must be in good general health, based on medical history. Each subject must have a appropriately signed informed consent. The parent or guardian of a child subject must be willing to allow other household members to be screened for head lice. If other household members are found to have a head lice infestation, they should also be enrolled in the study. If other household members are not willing to enroll in the study or do not qualify for enrollment, they must be willing to use the standard course of OTC lice treatment at home. Subjects must agree to not use any other form of lice treatment during the course of the study. Subjects must also agree not to use a lice comb during the course of the study. Subjects must agree not to cut or chemically treat their hair in the period between the Baseline treatment and the Day 14 visit. Exclusion Criteria: Individuals with history of irritation or sensitivity to pediculicides or hair care products. Individuals with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation. Individuals previously treated with a pediculicide within the 4 weeks prior to the study. Individuals who have used hair dyes, bleaches, permanent wave or relaxing solutions within the past 2 weeks or during the study. Individuals with a condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol. Individuals receiving systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results. Individuals who have participated in a clinical trial within the past 30 days. Individuals who, in the opinion of the investigator, do not understand the subject requirements for study participation and/or may be likely to exhibit poor compliance. Individuals with family members who are infested with lice but are unwilling or unable to enroll in the study or to ouse the standard course of lice treatment. Females who are pregnant or nursing. Sexually active females not using effective contraception. Individuals who have a history of drug abuse in the past year.

Sites / Locations

  • Hill Top Resesarch
  • Hill Top Research
  • Hill Top Research

Outcomes

Primary Outcome Measures

Efficacy variable: The presence/absence of live lice and/or nits at Day 7 and Day 14.
Safety Analyses: The assessment of safety will be based on frequency of adverse events and on the scalp evaluations for irritation.

Secondary Outcome Measures

Full Information

First Posted
April 4, 2006
Last Updated
July 11, 2006
Sponsor
ParaPRO LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00311779
Brief Title
A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis
Official Title
Phase 2 Study of Efficacy and Safety of Different Strengths of Spinosad Topical Creme Rinse (0%, 0.5% or 1.0%) in Subjects 2 Years of Age or Older With Pediculosis Capitis - A Dose Ranging Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2006
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2006 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
ParaPRO LLC

4. Oversight

5. Study Description

Brief Summary
The primary objective of the study is to determine the safety and efficacy of different strengths of Spinosad topical creme, as compared to a vehicle control, in subjects who have been infested with at least a mild case of Pediculosis capitis (head lice).
Detailed Description
There are millions of children and adults affected with head lice each year in the United States. It has become a major nuisance in school children resulting in many lost school days and frustrated parents. Lice and nit (ova) resistance to current OTC products has been reported. Compliance with product instructions is thought to be low. Therefore a safe and effective alternative to these products is desirable. Spinosad and its formulations have been approved by the Environmental Protection Agency as crop protection products in the US, Canada and Australia, and has received provisional approval in the UK, Spain and several other European Union countries. Spinosad is being formulated as a creme rinse using excipients that are widely used and are "generally regarded as safe" (GRAS). This study is intended to show the safety and efficacy of Spinosad 0.5% and 1.0%, as compared to the vehicle control in subjects 2 years of age and older with at least a mild infestation of pediculosis capitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pediculosis Capitis (Head Lice)
Keywords
Pediculosis capitis, Head Lice, Crawlers, Ova

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
Single
Allocation
Randomized
Enrollment
120 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Spinosad Creme Rinse
Primary Outcome Measure Information:
Title
Efficacy variable: The presence/absence of live lice and/or nits at Day 7 and Day 14.
Title
Safety Analyses: The assessment of safety will be based on frequency of adverse events and on the scalp evaluations for irritation.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subject must have head lice infestation of at least a mild severity present at baseline of at least 3 live lice and the presence of nits; Subject can be either male or female, 2 years or older Subject must be in good general health, based on medical history. Each subject must have a appropriately signed informed consent. The parent or guardian of a child subject must be willing to allow other household members to be screened for head lice. If other household members are found to have a head lice infestation, they should also be enrolled in the study. If other household members are not willing to enroll in the study or do not qualify for enrollment, they must be willing to use the standard course of OTC lice treatment at home. Subjects must agree to not use any other form of lice treatment during the course of the study. Subjects must also agree not to use a lice comb during the course of the study. Subjects must agree not to cut or chemically treat their hair in the period between the Baseline treatment and the Day 14 visit. Exclusion Criteria: Individuals with history of irritation or sensitivity to pediculicides or hair care products. Individuals with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation. Individuals previously treated with a pediculicide within the 4 weeks prior to the study. Individuals who have used hair dyes, bleaches, permanent wave or relaxing solutions within the past 2 weeks or during the study. Individuals with a condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol. Individuals receiving systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results. Individuals who have participated in a clinical trial within the past 30 days. Individuals who, in the opinion of the investigator, do not understand the subject requirements for study participation and/or may be likely to exhibit poor compliance. Individuals with family members who are infested with lice but are unwilling or unable to enroll in the study or to ouse the standard course of lice treatment. Females who are pregnant or nursing. Sexually active females not using effective contraception. Individuals who have a history of drug abuse in the past year.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dyal Garg, PhD
Organizational Affiliation
Hill Top Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Lewine, MD
Organizational Affiliation
Hill Top Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael Noss, MD
Organizational Affiliation
Hill Top Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hill Top Resesarch
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85251
Country
United States
Facility Name
Hill Top Research
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33409
Country
United States
Facility Name
Hill Top Research
City
Miamiville
State/Province
Ohio
ZIP/Postal Code
45147
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis

We'll reach out to this number within 24 hrs